Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?

Comparing a group of infants treated with recombinant erythropoietin and iron supplementation to a group of control infants, no difference was observed concerning the transfusion need. The incidence of retinopathy of prematurity was significantly higher in the treated group. These data need to be co...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pediatrics 2000-08, Vol.159 (8), p.627-628
Main Authors: ROMAGNOLI, C, ZECCA, E, GALLINI, F, GIRLANDO, P, ZUPPA, A. A
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood Transfusion
Emergency and intensive care: neonates and children. Prematurity. Sudden death
Erythropoietin - adverse effects
Ferric Compounds - adverse effects
Ferritins - blood
Hematocrit
Humans
Incidence
Infant, Newborn
Intensive care medicine
Medical sciences
Ophthalmology
Recombinant Proteins
Respiratory Distress Syndrome, Newborn - therapy
Retinopathies
Retinopathy of Prematurity - classification
Retinopathy of Prematurity - diagnosis
Retinopathy of Prematurity - etiology
Severity of Illness Index
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Comparing a group of infants treated with recombinant erythropoietin and iron supplementation to a group of control infants, no difference was observed concerning the transfusion need. The incidence of retinopathy of prematurity was significantly higher in the treated group. These data need to be confirmed in randomized controlled studies.
ISSN:0340-6199
1432-1076
DOI:10.1007/PL00008390